Lilly Says CMS Review Of Beta-Amyloid PET Goes Beyond Medicare Statutory Criteria
This article was originally published in The Pink Sheet Daily
Executive Summary
“Improvement in health outcomes” standard would interpret “the statute to require both diagnosis and treatment,” Lilly says about CMS’ recent evaluation of beta-amyloid positron emission tomography in dementia and neurodegenerative disease.